Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria
Pediatric Allergy and Immunology · 2025
DOI: 10.1111/pai.70216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, 2025. Verfasst von Canan Caka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Omalizumab is an effective treatment option for antihistamine‐resistant chronic spontaneous urticaria (CSU) patients. This study aimed to evaluate relapse in patients after completing omalizumab treatment and identify associated risk factors.
Methods
Patients aged 12–18 years diagnosed with CSU who received omalizumab therapy between 2015 and 2023, whose treatment ceased with complete remission by December 2024.
Results
This study consisted of 59 patients with a median (interquartile) age of 14.0 (12.0–16.0) years, of whom 49.2% were female. Post‐treatment relapse was observed in 47.4% ( n = 28) of the patients, with a median time to relapse of 6.0 (4.0–7.5) months. Relapsed patients had an earlier onset of CSU than non‐relapsed [11.9 (8.0–13.9) and 14.1 (11.5–15.9) years, p = .028]. The pre‐treatment symptom duration was significantly longer in relapsed patients than in non‐relapsed patients [21.0 (8.0–36.0) and 8.0 (6.0–21.0) months, p = .010]. Patients with symptoms longer than 7.5 months prior to starting omalizumab had a higher risk of relapse (AUC: 0.695, 95% CI: 0.561–0.830; p = .010; sensitivity: 82.1%, specificity: 45.2%). Pretreatment symptom duration was identified as a significant risk factor, increasing the likelihood of relapse (OR: 1.134, 95% CI: 1.011–1.272, p = .032). No significant differences were found between relapsed and non‐relapsed patients in terms of other clinical and laboratory factors. Late relapse was more common in ANA‐positive patients than early relapse [14 (87.5%) vs. 2 (12.5%), p = .021].
Conclusion
Delayed initiation of omalizumab treatment following the onset of urticaria symptoms is associated with an increased risk of relapse. Therefore, omalizumab treatment should be initiated promptly in eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Allergy, Hacettepe University School of Medicine, Ankara, Turkey.
ORCID-Profile: Canan Caka, Melike Ocak, Bahri Can Duran, Özge Soyer, Bülent Enis Sekerel, Ümit Murat Şahiner
Zitieren
APA
Caka, C., Ocak, M., Duran, B. C., Soyer, Ö., Sekerel, B. E., & Şahiner, Ü. M. (2025). Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.70216
Vancouver
Caka C, Ocak M, Duran BC, Soyer Ö, Sekerel BE, Şahiner ÜM. Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria. Pediatric Allergy and Immunology. 2025. doi:10.1111/pai.70216
BibTeX
@article{Caka2025,
author = {Caka, Canan and Ocak, Melike and Duran, Bahri Can and Soyer, Özge and Sekerel, Bülent Enis and Şahiner, Ümit Murat},
title = {Relapse rates and associated risk factors following omalizumab treatment in adolescents with chronic spontaneous urticaria},
journal = {Pediatric Allergy and Immunology},
year = {2025},
doi = {10.1111/pai.70216}
}
EUVIMED